According to filings with the U.S. Securities and Exchange Commission, Cleveland Diagnostics, Inc. is raising up to $14,421,653.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Cleveland Diagnostics, Inc.
Cleveland Diagnostics offers a novel class of simple blood tests that help identify presence or absence of disease. Our first product, IsoPSA, meets the chronic unmet need of a simpler, clearer way to rule out unnecessary prostate biopsies. We envision the day when a cancer diagnosis is no longer feared. With our proprietary IsoClear platform leading the way, were giving physicians and their patients more definitive cancer insight earlier, allowing critical and even lifesaving decisions to be made sooner.

To learn more about Cleveland Diagnostics, Inc., visit https://www.clevelanddx.com/
Cleveland Diagnostics, Inc. Linkedin Page: https://www.linkedin.com/company/cleveland-diagnostics-inc./

Contact:
Arnon Chait, Chief Executive Officer
216-432-9050
https://www.linkedin.com/in/arnonchait/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.